Skip to main content

Table 2 Summary of studies which investigated treatment uptake

From: A systematic review of community based hepatitis C treatment

Study Study population and policy for initiating treatment (if included in publication) Facility N OST (%) Active illicit substance use Treatment uptake
n (%)
Bruce HCV infection +/− HIV
Attendance at OST clinic
Rx according to published guidelines and the same in both facilities
Tertiary 9 100 Opioid negative on urine toxicology in past 30 days 4 (44)
Primary 12 100 Opioid negative on urine toxicology in past 30 days 12 (100)
Gigi HCV antibody positive
Attended Liver clinic or OST clinic
Policy for Rx initiation not published
Tertiary 643 0 Nil 276 (43)
Primary 204 100 Nil 17 (8)
Kramer HCV infection
Designated Primary Care Provider
Majority of care from one Veterans Affairs facility
Rx indicated if more than portal fibrosis and no contraindications (including no active illicit drug use)
Specialist clinic 24,853 N/P N/P 3537 (14)
Primary clinic 1929 N/P N/P 251 (13)
Kuo HCV antibody positive
Participation in screening program
Pre-intervention Rx if: ALT >40 (once) and > F1 or HCV RNA positive
Post intervention Rx if ALT >80 (twice) and > F1
Pre intervention 18 N/P N/P 4 (22)
Post intervention N/P N/P 3 (19)
Moriarty HCV infection
Attendance at outreach clinic
Policy for Rx initiation not published
Tertiary 51 N/P N/P 1 (2)
Primary N/P N/P 4 (8)
Moussalli HCV infection
Attendance at OST Primary healthcare facility
Rx if > F2 fibrosis
Pre-intervention 337 N/P N/P 2 (0.6)
Post intervention N/P N/P 85 (25)
  1. OST opioid substitution therapy, N/P not provided, Rx treatment